|
|
Post by lakers on Oct 6, 2019 12:12:11 GMT -5
Right on cue when A, TS progress, LFD strikes again. It’s a good sign that LFD feels insecure. MannKind's Technosphere Platform Issues Are Worth Discussing $MNKD seekingalpha.com/article/4295249 |
|
|
|
Post by babaoriley on Oct 6, 2019 12:28:56 GMT -5
No coincidence that’s for sure.
|
|
|
|
Post by radgray68 on Oct 6, 2019 12:47:50 GMT -5
Classic hit piece. Lots of straw man arguments. Agreed, on the timing.
|
|
|
|
Post by letitride on Oct 6, 2019 13:07:42 GMT -5
LFD? I got an acronym for that but I got a feeling mine aint it, even if it probably should be.
|
|
|
|
Post by apidistra on Oct 6, 2019 13:22:12 GMT -5
The writer is, apparently, nameless. But he takes his moniker from Diogenes: THE CYNIC!!! What else do you need to know about him?
A retired textbook salesman. Eminently qualified to appraise MNKD, its technology, personnel and prospects!
"In the nearly five years I’ve written articles about the company the internal deterioration has continued unabated."
Hogwash, pish-tosh, nonsense and total CRAP!
|
|
|
|
Post by longliner on Oct 6, 2019 13:51:21 GMT -5
Without fear, we will never move up.
|
|
|
|
Post by lakers on Oct 6, 2019 14:02:11 GMT -5
|
|
|
|
Post by apidistra on Oct 6, 2019 14:22:28 GMT -5
There is no need to be profane.
|
|
|
|
Post by ktim on Oct 7, 2019 17:45:09 GMT -5
That guy is the biggest joke. I couldn't even make it past the point where he is trying to imply TS particles should be governed by similar aerodynamics as a plane. Have I missed the fact that TS particles have very tiny wings? HA... this man is incredibly stupid or at least hopes his readers are.
|
|
|
|
Post by brotherm1 on Oct 7, 2019 17:45:35 GMT -5
Looks like he shot a dud
|
|
paul
Researcher
Posts: 134
|
Post by paul on Oct 8, 2019 22:01:10 GMT -5
I think he does make a point in that if the CEO's claim about 70% delivery is accurate, then what's the explanation for "Following oral inhalation of AFREZZA, a mean of 39% of the inhaled dose of carrier particles was distributed to the lungs..."? Was the CEO referring to other drug/technosphere combinations?
|
|
|
|
Post by sayhey24 on Oct 9, 2019 6:24:13 GMT -5
I thought this comment was interesting "Of the 17 companies, he (Al Mann) personally took two of them into the public market---MannKind and Second Sight Medical Products.
The last I checked Minimed Technologies was publicaly traded. In April 2001 it was trading for about $25pps and in May sold to Medtronic at $48. Al Mann was often quoted that he believed MNKD is worth significantly more. We will see but afrezza has actually been working better than most predicted and with no lung function issues. Its also looking like Technosphere is catching on in the market for other molecules.
|
|
